# A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers

> **NCT03698695** · PHASE1 · COMPLETED · sponsor: **Theranexus** · enrollment: 152 (actual)

## Conditions studied

- Cognitive Impairment
- Alzheimer Disease

## Interventions

- **DRUG:** THN 201
- **DRUG:** Donepezil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03698695
- **Lead sponsor:** Theranexus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2019-10-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698695, "A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03698695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*